Document Z4e4v7qD0X1XeyJpOpv00OkNZ

DRAFT CINPATHOGEN DELIVERABLES 2. Provide a benzene job-exposure matrix for cases and controls used in the casecontrol study. The matrix will consider job, task, industry and time period in developing exposure estimates to benzene. Data sources for exposure assessment including the IPHS data set, Yang Pu database, the Chinese literature, real-time monitoring in selected factories and simulations will be used to arrive at credible benzene exposure estimates. 3. Provide a test data set consisting of all diagnosed and verified AMLs and lymphoid neoplasms (WHO 2001) and their matched controls, including detailed subtype diagnostic classifications, confounders and job-exposurem!~:trix, and all questionnaire information (such as medical histories, f9:ffi!!!~histories, lifestyle information, etc.) for testing the case-control protocq!~~~lor developing analytical programs to Applied Health Sciences by mid-Sept~~p~~~Q07*. [ROW - Talk to Rob Schnatter/Otto Wong] 4. Provide a final data set consisting of all <I:::::::::d v:::,~!I!~III~M~S and lymphoid neoplasms (WHO 2001) and their including def~!i~9 subtype diagnostic classifications, matrix, and~!b. questionnaire information (such as histories, Hf~style information, etc.) for completion of the to Applied Health Sciences by July 1,2008*. 5. Provide an account of all participating hospitals, who including their basic interview (if patients at all who were not interviewed, for non-participation/non- *Based on a timeline 1. presenting the findings of the Disease the in Cinpathogen's March 18, 2007 3.1-A by November 1, 2008 1. manuscript(s) presenting the findings of the Molecular following the guidelines in Cinpathogen's March 18, 2007 3.1-A by November 1, 2008. Project 1. Implementation of the conditions one and three in the agreement for advance funding for Cinpathogen (Red Cavaney to Richard Irons, April 11, 2007). 2. Implementation of recommendations from the independent QA/QC team. 3. Provide semi-annual progress report to the Scientific and Ethics Review Panelists, Shanghai Health Study sponsors, and API. The update should include a cumulative 2 SH ELL-MCCLU RG-059444